183.09
前日終値:
$185.72
開ける:
$185.35
24時間の取引高:
4.78M
Relative Volume:
0.62
時価総額:
$323.41B
収益:
$57.37B
当期純損益:
$4.20B
株価収益率:
77.91
EPS:
2.35
ネットキャッシュフロー:
$15.39B
1週間 パフォーマンス:
+0.71%
1か月 パフォーマンス:
-4.81%
6か月 パフォーマンス:
+0.01%
1年 パフォーマンス:
+17.86%
Abbvie Inc Stock (ABBV) Company Profile
ABBV を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ABBV
Abbvie Inc
|
183.09 | 321.13B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
LLY
Lilly Eli Co
|
719.39 | 670.62B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
152.43 | 368.56B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
NVS
Novartis Ag Adr
|
111.87 | 222.75B | 53.22B | 12.86B | 14.85B | 6.39 |
![]()
NVO
Novo Nordisk Adr
|
68.60 | 303.04B | 43.59B | 15.04B | 10.74B | 3.3766 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
2024-12-10 | 再開されました | BofA Securities | Neutral |
2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-11-15 | 開始されました | Wolfe Research | Outperform |
2024-11-04 | アップグレード | Argus | Hold → Buy |
2024-10-17 | 開始されました | Bernstein | Mkt Perform |
2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
2023-12-11 | アップグレード | Goldman | Neutral → Buy |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
2023-10-20 | 再開されました | UBS | Neutral |
2023-09-29 | 開始されました | Raymond James | Outperform |
2023-07-25 | 開始されました | William Blair | Mkt Perform |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-04-05 | ダウングレード | Argus | Buy → Hold |
2023-03-01 | 開始されました | Guggenheim | Buy |
2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
2022-11-18 | 開始されました | Credit Suisse | Outperform |
2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
2022-05-23 | 開始されました | SVB Leerink | Underperform |
2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2022-04-06 | 再開されました | Morgan Stanley | Overweight |
2022-02-28 | ダウングレード | UBS | Buy → Neutral |
2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
2022-02-03 | 繰り返されました | Barclays | Equal Weight |
2022-02-03 | 繰り返されました | BofA Securities | Neutral |
2022-02-03 | 繰り返されました | Goldman | Neutral |
2022-01-13 | 開始されました | Redburn | Buy |
2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
2021-12-09 | 再開されました | Wells Fargo | Overweight |
2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
2021-07-27 | 再開されました | Truist | Buy |
2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
2020-11-10 | 再開されました | Bernstein | Outperform |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-06-02 | アップグレード | Argus | Hold → Buy |
2020-05-18 | 再開されました | BofA/Merrill | Neutral |
2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
2020-05-11 | 再開されました | Morgan Stanley | Overweight |
2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
2020-02-27 | 開始されました | Barclays | Equal Weight |
2020-02-06 | 開始されました | Mizuho | Buy |
2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
2019-12-26 | 繰り返されました | Cowen | Outperform |
2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2019-05-28 | 開始されました | Goldman | Neutral |
2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies - marketscreener.com
CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers - Yahoo Finance
Bearish Sentiment and Increased Put Activity for AbbVie (ABBV) | - GuruFocus
Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies - BioSpace
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - sharewise
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
AbbVie’s Allergan cuts over 200 staff after botched marketing campaign - PharmaLive
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN
AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - Benzinga
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Investing News Network
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio | ABBV Stock News - GuruFocus
Tissue Engineering Market Generated Opportunities, Future - openPR.com
Prurigo Nodularis Market - GlobeNewswire Inc.
AbbVie’s SWOT analysis: biopharma giant faces pipeline challenges amid stock growth - Investing.com
Precision immunology Market Growth in Future Scope 2025-2032 | - openPR.com
Immunomodulatory Drugs Market in 2025 Detailed Study Analysis | - openPR.com
Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie - insights.citeline.com
CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - MSN
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result - The Motley Fool
Key Drivers Behind AbbVie’s (ABBV) Performance - Insider Monkey
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com
AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel - Yahoo Finance
AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient - Investing News Network
AbbVie Secures Legal Victory Over Allergan Share Dispute - USA Herald
Interleukin Inhibitors Market Detailed In New Research Report - openPR.com
AbbVie (ABBV) has a Stable and Highly Profitable Business Model - Insider Monkey
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change - Pharma Voice
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com
AbbVie Gets Victory In Allergan Shareholder Suit Upheld - Law360
Court upholds dismissal of AbbVie-Allergan merger suit - Crain's Chicago Business
AbbVie, Allergan Merger Suit Dismissal Upheld By Illinois Court - Bloomberg Law News
Cancer Cachexia Market Detailed in New Research Report By 2032 | AbbVie Inc., Actimed Therapeutics - openPR.com
Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail
Plastic Surgery Market Fly Massive Growth in Years to Come: AbbVie, Johnson & Johnson Services, Sientra - openPR.com
AbbVie Hits Last Generic-Orilissa Holdout With New Patent Suit - Bloomberg Law News
AbbVie (ABBV) Soared on Favorable Tailwinds - MSN
Ameriprise Financial Initiates AbbVie at Buy - marketscreener.com
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class ActionABBV - Morningstar
Former AbbVie, Takeda omnichannel lead Dan Gandor joins Eversana Intouch - Medical Marketing and Media
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class ActionABBV - marketscreener.com
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie - Yahoo Finance
Perion, Sea, KKR, Chimera, AbbVie: Trending by Analysts - TipRanks
Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock” - MSN
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear - simplywall.st
Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings - Yahoo Finance
3 Stocks That Will Profit From Trump's Drug Price CutAbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN) - Benzinga
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - TradingView
7th Circ. Weighs AbbVie Whistleblower's Drug Marketing Suit - Law360
AbbVie’s Solid Tumor Strategy Gets a Win With Accelerated FDA Approval in Lung Cancer - MedCity News
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):